St Stephen’s AIDS Trust

Clinical Research Publications 2008 – 2014



St Stephen’s Centre, 369 Fulham Road, London SW10 9NH
Tel: 020 3315 6136
Registered Charity: 11034163
Registered in England Company Number: 7134218



St Stephen’s AIDS Trust
Clinical Research Publications 2008 – 2014

The St Stephen’s AIDS Trust is a UK clinical research charity
based at the Chelsea and Westminster Hospital in London.
The Charity was founded in 1991 by Professor Brian
Gazzard and a team of colleagues in response to the HIV/
AIDS global pandemic and its impact on people effected
by and living with HIV in the United Kingdom.
St Stephen’s AIDS Trust mission statement is to:

“promote clinical research into the treatment of HIV and
those infections and malignancies associated with the
acquired immunodeficiency syndrome (AIDS), in particular
the research undertaken at the Chelsea and Westminster
Hospital, and to publish such research. It also promotes
education regarding all aspects and matters relating to HIV
by providing information, training and advice throughout
the world”.
Over the last 30 years the Charity has been at the
forefront of clinical research studies, from the early
nucleoside reverse transcriptase inhibitor studies in the
1980s, to the current range of successful highly active antiretroviral therapy studies. The Charity’s research activities
have produced, in the last 10 years alone, over 500 clinical
research papers. A selection of some 300 of these papers
has been collected together in this publication.

Charity has developed a strong track record in clinical
research through the continued investment in its research
infrastructure and capability, such as its dedicated
Phase I–IV PK and Clinical Trials Unit at the Chelsea and
Westminster Hospital. As well as these physical facilities,
the Charity has the capability to sponsor and manage
multi-centred clinical research studies, in the UK and
internationally, through its established service teams in
regulatory, compliance, project management, logistics,
data management and statistics. A range of leading
medical and scientific experts in HIV medicine, immunology
and infectious diseases supports this infrastructure and
capability in clinical research.
As the selection of papers included in this publication
suggest, the Charity has successfully managed a diverse
range of relationships and partnerships. These include
many international pharmaceutical companies; a number
of influential global NGO’s (Bill and Melinda Gates
Foundation, International AIDS Vaccine Initiative); key
UK public research bodies (MRC, NHIR, Public Health);
academic institutions from the UK and across the world;
and, as equally important, individual researchers, scientists
and clinicians.

If you are interested in finding out more about the work of the Charity, exploring possible clinical research collaborations and
partnerships or accessing its managed services for conducting clinical research in the UK and internationally, please contact:
General (Charity) enquiries: Linda Connor, Admin Manager: 020 3315 6136
PK and Clinical Trials Unit: Carl Fletcher, Associate Director: 020 3325 6325
Clinical Research Organisation Services: Ruth Bateson, Associate Director: 020 3315 6563




Writing group. Williams I, Churchill D, Anderson J, Boffito M,
Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher
M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson
M, Khoo S, Leen C, Marshal N, Nelson M, Orkin C, Paton N,
Philips, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski
A, Waalsh J, Waters L, Wilkins E, Winston A, Youle M
British HIV Association Guidelines for the treatment of
HIV 1 positive adults with Antiretroviral therapy 2012
(updated 2013)
HIV Med 2014 Mar; 15 supp 2. 1-9

Parikh ND, Martel-Laferriere V, Kushner T, Childs K, Vachon
ML, Dronamraj D, Taylor C, Fiel MI, Schaino T, Nelson M,
Agarwal K, Dieterich DT
Clinical factors that predict noncirrhotic portal
hypertension in HIV infected patients: Proposed
diagnostic algorithm
J Infect Dis 2014 Mar; 209 (5): 734-8

Chacko L, Chamberlain F, Mandalia S, Nelson M

Do resistance patterns vary between different FTC
contain drug regimens?
J Infect 2014 Feb 8 2014

McFaul K, Liptrott N, Cox A, Martin P, Egan D, Owen A, Kelly
S, Karolia Z, Shaw K, Bower M & Boffito M.

Evolution of cellular and viral resistance in HIV patients
diagnosed with lymphoma receiving chemotherapy and
combination antiretroviral therapy.
HIV Medicine 2014, 15 (suppl 3) 53

May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S,
Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post Fisher M, Ainsworth J, Jose S, Leen
C, Nelson M, Anderson J, Sabin C: for the UK Collaborative
HIV cohort (UK CHIC) study
Impact on life expectancy of HIV 1 positive individuals
of CD4+ cell count and Viral load response to
antiretroviral therapy: UK cohort study
AIDS 2014 Feb 19

Longley J, Redlin S, Balachandran K, Holmes P, Nelson M &
Bower M.
Non-Hodgkin’s lymphoma (NHL): Does being on cART
before diagnosis make a difference?
HIV Medicine 2014, 15 (suppl 3) 55

Tull T, Papineni P, Cook C, Mee J, Bower M, Morar N,
Nelson M

Paraneoplastic pemphigus in patient infected with HIV
Clin Exp Dermatol. 2014 Jan ; 39 (1): 83-5
Raman L, Nelson M

Prospective stage stratified approach to AIDS related
Kaposi’s Sarcoma
J Clin Virol 2014 Feb 2

Smith M, Pealing J, McCann S, Balachandran K, Nelson M &
Bower M
Second malignancies in patients with Kaposi’s sarcoma
(KS): Does systemic chemotherapy contribute to risk?
HIV Medicine 2014, 15 (suppl 3) 8.

Keay R, Singh G, Abdul-Latif M, Rayment M, Nelson M

Shigella flexneri enteritis in risk- taking HIV infected

Chacko L, Chamberlain F, Mandalia S, Nelson M

J Infect 2014 Jan; 68 (1); 103-4

J Acqui Immune Defic Syndr 2014 Jan 1; 65 (1): 78-81

Ferras Alwan, Annie He, Silvia Montoto, Shireen Kassam,
Matthew Mee, Fiona Burns, Simon Edwards, Andy Wilson,
Melinda Tenant-Flowers, Robert Marcus, Kirit M. Ardeshna,
Mark Bower, Kate Cwynarski.

Five-year safety evaluation of Maraviroc in HIV 1
infected treatment experienced patients

Nightingale A, Ratcliffe D, Leonidou L, Margetts A, Asboe D,
Gazzard B, Catalan J, Barber TJ.
HIV-related neurocognitive impairment screening: the
patient’s perspective on its utility and psychological
AIDS Care. 2014 Mar 13

Dhoot S, Balachandran K, Tittle V, Bunker C, Nelson M,
Kelleher P & Bower M

Immunological function in HIV-seronegative men
who have sex with men (MSM) and Kaposi’s sarcoma
HIV Medicine 2014, 15 (suppl 3) 55.


The addition of Rituximab to CODOX-M/IVAC
chemotherapy in the treatment of Burkitt lymphoma is
safe and associated with increased efficacy in the HIV
positive population.
EHA 2014.

Bulteel N, Banso-Matharu L, Churchill D, Dunn D, Bibby D,
Hill T, Nelson M, CHIC study group; UK Drug resistant Database (UK HDRD) Study Group
The emergence of drug resistant HIV variants at
virological failure of HAART combination containing
efavirenz, Tenofovir and lamivudine or emtricitabine
within the UK collaborative HIV cohort
J Infect 2014 Jan; 68 (1): 77-84



Rayment M, Doku E, Thornton A, Pearn M, Sudhanva M,
Jones R, Nardone A, Roberts P, Tenant-Flowers M, Anderson
J, Sullivan AK and Mark Atkins

Jackson A, Kløverpris HN, Boffito M, Handley A, Atkins M,
Hayes P, Gilmour J, Riddel L, Chen F, Bailey-Tippets M, Walker B, Ackland J, Sullivan M, Goulder P
A Randomised, Placebo-Controlled, First-In-Human
Study of a Novel Clade C Therapeutic Peptide Vaccine
Administered Ex Vivo to Autologous White Blood Cells
in HIV Infected Individuals.
PLoS One. 2013;17.

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR,
Domingo P, Granier C, Pearce H, Sedani S, Gartland M,
Team A.

96-Week results of abacavir/lamivudine versus
tenofovir/emtricitabine, plus efavirenz, in antiretroviralnaive, HIV-1-infected adults: ASSERT study.
Antivir Ther. 2013 Jul 31
Pozniak AL, Arribas JR.

A benchmark for management of drug resistant HIV.
Lancet Infect Dis. 2013 Jul;13(7):561-2
Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S,
Nelson M, Montoto S; Tennant-Flowers M, Burns F, Marcus
R, Edwards SG, Cwynarski K
A retrospective multi-centre analysis of treatment
intensification for HIV positive patients with high risk
diffuse large B cell lymphoma
Leuk Lymphoma 2013 Sep; 54 (9): 1921-7

Martin TC, Martin NK, Naresh KN, Nelson M

A traumatic splenic rupture secondary to chronic HIV
Int J STD AIDS 2013 Dec; 24 (12) 989-91

Revell AD, Wang D, Wood R, Morrow C, Templeman H,
Hamers R, Alvarez-Uria G, Streinu-Cercel A, Ebe L, Wensing
A Reiss P, van Sigham AI, Nelson M, Emery S, Montanr JSm,
Lane HC, Larder BA;on behalf of RDI group
An update to the HIV – TrePS system: the development
of new computational models that do not require a
genotype to predict HIV treatment outcomes
J Antimicrob Chemother 2013 Nov 24

Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D,
Kingston MA, Thng C, McCormack S, Gill ON, Nardone A;
Audit of HIV testing frequency and behavioural
interventions for men who have sex with men: policy
and practice in sexual health clinics in England
Sex Transm Infect 2013; 89:404-8

Automatic Oral Fluid-Based HIV Testing in HIV Screening
HIV Med 2013; 14 Suppl 3:49-52

Abdel Malek R, Cox S, Bower M, Farag D & Alsirafy S.

Availability of informal caregivers for palliative care
patients with cancer: Is there a difference between
higher and lower income settings?
Eur J Cancer, 2013: 49/S2, S291.

Mehta P, Nelson M, Brand A, Boag F
Avascular necrosis in HV

Hematol Int. 2013 Jan; 33 (1): 235-8
Girad PM, Nelson M, Mohammed P, Hill A, van Delft Y,
Moecklinghoff C

Can we stop CD4+ testing in patients with HIV 1 RNA
suppression on antiretroviral treatment?
AIDS 2013 Nov 13; 27 (17): 2759-63

Jagit Singh GK, Ijaz S, Rockwood N, Farnworth SP, Devitt
E, Atkins M, TedderR, Nelson M.

Chronic Hepatitis E as a cause for cryptogenic cirrhosis
in HIV
J. Infect 2013 Jan; 66 (1): 103-6

Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N,
Ringner-Nackter L, Karolia Z, Gazzard B, Boffito M
Coadministration of atazanavir-ritonavir and
zinc sulfate: impact on hyperbilirubinemia and
Antimicrob Agents Chemother. 2013;57:3640-4.

Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd
P, Dejesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G,
Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS,
Cheng AK
Cobicistat Versus Ritonavir as a Pharmacoenhancer
of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil
Fumarate in Treatment-Naive HIV Type 1-Infected
Patients: Week 48 Results.
J Infect Dis. 2013;208:32-9

Bower M, Della Pria A, Flook M, Hayward K, Januszewski A,
Williams J & Nelson M
Comparison of two diagnostic criteria schemes for
multicentric Castleman’s disease in 72 cases.
HIV Medicine 2013, 14 (suppl 2) 28




2013 continued
Revell AD, Wang D, Wood R, Morrow C, Templeman H,
Hamers RL, Alvarez-Uria G, Steinu-Cercel A, Ene L. Wensing
AM, DeWolf F, Nelson M, Montaner JS, Lane HC, Larder BA,
RDI study group
Computation models can predict response to HIV
therapy without a genotype and may reduce treatment
failure in different resource limited settings
J Antimicrob Chemother 2013 June; 68 (6); 1406-14

Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA,
Kaplan R, Lazzarin A, Valdez H, Goodrich J, Mori J, Craig C,
Tawadrous M

Efficacy and safety of lersivirine (UK-453,061) versus
efavirenz in antiretroviral treatment-naive HIV-1infected patients: week 48 primary analysis results from
an ongoing, multicenter, randomized, double-blind,
phase IIb trial
J Acquir Immune Defic Syndr. 2013 Feb

Nithianathan V, Singh GKJ, Bower M & Nelson M

Raben D, Delpech V, de Wit J, Sullivan A, Lazarus J, Dedes
N, Coenen T, Lundgren J;

Emerging patterns of integrase inhibitor

HIV Med 2013; 14 Suppl 3:1-5

O’Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay
P, Chadwick D,, Fisher M, Ainsworth J, Gilson R, Mackie N,
Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman
A, Post F, Johnson M, Sabin CA, Phillips AN

Conclusions from the HIV in Europe Copenhagen 2012
Conference and ways forward: working together for
optimal HIV testing and earlier care

Rice B, Elford J, Yin Z, Kruijshaar M, Abubakar I, Lipman M,
Pozniak A, Kall M, Delpech V.

Decreasing incidence of tuberculosis among
heterosexuals living with diagnosed HIV in England and
AIDS. 2013 Apr 24;27(7):1151-7.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C,
Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie
J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T,
Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D,
Underwood M, Griffith S, Min S; extended SAILING Study

Dolutegravir versus raltegravir in antiretroviralexperienced, integrase-inhibitor-naive adults with HIV:
week 48 results from the randomised, double-blind,
non-inferiority SAILING study
Lancet. 2013 Aug 24;382(9893):700-8.

Beckett H, Abdul-Latif M, Mandalia S, Singh GKJ, Bower M &
Nelson M.

HIV Medicine 2013, 14 (suppl 2) 24

Failure to achieve a CD4+ cell count response in
combination antiretroviral therapy despite consistent
viral load suppression
AIDS 2013 Dec 11

Rayment M, Sullivan AK

Failure to test for HIV infection; A medicolegal
Casebook 2013 21; 1: 7

Sullivan AK, Raben D, Reekie J, Rayment M, Mocroft A, Esser
S, Leon A, Begovac J, Brinkman K, Zangerle R, Grzeszczuk A,
Vassilenko A, Hadziosmanovic V, Krasnov M, Sönnerborg A,
Clumeck N, Gatell J, Gazzard B, Monforte Ad, Rockstroh J,
Lundgren JD
Feasibility and Effectiveness of Indicator ConditionGuided Testing for HIV: Results from HIDES I (HIV
Indicator Diseases across Europe Study
PLoS One 2013; 8(1):e52845. Epub 2013 Jan 15

Effect of bisphosphonates on the treatment of BMD
abnormalities in an HIV-1 minfected cohort

Lewitsching S, Gedela K, Toby M, Kulasegaram R, Nelson M,
O’Doherty M, Cook GJ

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B; Gilson R, Orkin C, Johnson M, Palfreeman
A, Chadwick D, Leen C; Schwenk A, Anderson J, Gompels
M, Dunn D, Khoo S, Sabin C

Eur J Nucl Med MoL Imaging 2013 Sept; 40 (9); 1420 -7

HIV Medicine 2013, 14 (suppl 2) 39

Effects of age on antiretroviral plasma drug
concentration in HIV infected subjects undergoing
routine therapeutic drug monitoring
J Antimicrob Chemother 2013 June 68 (6) 1354-9


F-FDG PET/CT in HIV related central nervous system

Vispo E, Cevik M, Rockstroph JK, Barreiro P, Nelson M,
Scourfirled A, Wasmuth JC, Boesecke C, Soriano V,
European Network of Clinic Trials (NEAT)

Genetic determinants of idiopathic noncirrhotic ports
hypertension in HIV infected patients
Clin Infect Dis 2013 April; 56 (8): 1117 - 22



Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D,
Kingston MA, Thng C, McCormack S, Gill ON, Nardone A;

Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D,
Cummins N, Dalmau D, Dehovitz J, Lehmann C, Sullivan A,
Woolley I, Kuller L, Neaton JD, Tracy RP

Sex Transm Infect 2013; 89:404-8

J Am Heart Assoc 2013; 2(4):e000264

Audit of HIV testing frequency and behavioural
interventions for men who have sex with men: policy
and practice in sexual health clinics in England

C. Cevik M, Oh K, Scott S, Tan J, Bower M & Nelson M

Hepatic safety profile of antiretrovirals in individuals
infected with HIV and chronic hepatitis
HIV Medicine 2013, 14 (suppl 2) 70

INSIGHT SMART Study Team. HIV Replication Alters the
Composition of Extrinsic Pathway Coagulation Factors
and Increases Thrombin Generation.

Bashford J, Nelson M, Bower M, Atkins M

JC – a forgotten foe or a foe to be forgotten
IV Med 2013 May; 14 (5): 326

Martin TC, Martin NK, Hickman M, Vickerman P, Page EE,
Everett R; Gazzard BG, Nelson M

Gathogo EN, Hamzah L, Hilton R, Marshall N, Ashley C,
Harber M, Levy JB, Jones R, Boffito M, Khoo SH, Drage M,
Bhagani S, Post FA

AIDS 2013 Oct 23; 27 (16): 2551-7


Hepatitis C Virus reinfection incidence and treatment
outcomes among HIV positive MSM

Coutinho R, Flook M, Dalla Pria A, Gandhi S, Bailey K, Fields
P, Cwynarski K, Wilson A, Tenant-Flowers M, Marcus R,
Orkin C, Gribben JG, Montoto S, Bower M
HIV status does not influence the outcome of patients
diagnosed with DLBCL treated with R-CHOP in the
Haematologica, 2013; 98 (s1) 129.

Pozniak A, Rackstraw S, Deayton J, Barber T, Taylor S, Manji
H, Melvin D, Croston M, Nightingale S, Kulasegaram R,
Pitkanen M, Winston A.

HIV-associated neurocognitive disease: case studies and
suggestions for diagnosis and management in different
patient sub-groups.
Antivir Ther. 2013 Mar 21

Lawton MD, Nathan M, Asboe D.

HPV vaccination to prevent anal cancer in men who
have sex with men
Sex Transm Infect. 2013 Aug;89(5):342-3.
Barton SE and OMahoney C

HPV vaccination; reaping the rewards of the appliance
of science.
BMJ 2013;346:f2184

Van de Velde V, Nelson M, Bower M & Sonecha S.

Indications for changing to raltegravir therapy in patient
sixth pre-existing undetectable viral load
HIV Medicine 2013, 14 (suppl 2) 61

Kidney transplantation in HIV-positive adults: The UK

Bull L, Bower M & Nelson M.

Long-term therapeutic success of etravirine in switch
and naive patients.
HIV Medicine 2013, 14 (suppl 2) 57

Herasimtschuk AA, Hansen BR, Langkilde A, Moyle GJ,
Andersen O, Imami N

Low-dose growth hormone for 40 weeks induces
HIV-1-specific T cell responses in patients on effective
combination anti-retroviral therapy.
Clin Exp Immunol. 2013;173:444-53

Hughes G, Alexander S, Simms I, Conti S, Ward H, Powers C,
Ison C; on behalf of the LGV Incident Group.
Lymphogranuloma venereum diagnoses among men
who have sex with men in the UK: interpreting a
cross-sectional study using an epidemic phase-specific
Sex Transm Infect 2013 Jul 12

Sullivan AK, Savage EJ, Lowndes CM, Paul G, Murphy G,
Carne S, Back DJ, Gill ON

Non-disclosure of HIV status in UK sexual health clinics –
a pilot study to identify non-disclosure within a national
unlinked anonymous seroprevalence survey
Sex Transm Infect 2013; 89:120-1. Epub 2013 Feb 13

Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N,
Nelson M; Gazzard BG
Pancreatic insufficiency in patients with HIV
infection:role of didanosine questioned
HIV Med 2013 March; 14 (3): 161-6




2013 continued
Della Pria A, Holmes P, Alfa-Wali M, Fox P, McKenna H,
Nelson M & Bower M
Persistence of anal dysplasia following
chemoradiotherapy for anal cancer

Hayes P, Gilmour J, von Lieven A, Gill D, Clark L, Kopycinski
J, Cheeseman H, Chung A, Alter G, Dally L, Zachariah D,
Lombardo A, Ackland J, Sayeed E, Jackson A, Boffito M,
Gazzard B, Fast PE, Cox JH, Laufer D

Safety and immunogenicity of DNA prime and modified
vaccinia ankara virus-HIV subtype C vaccine boost in
healthy adults

HIV Medicine 2013, 14 (suppl 2) 28

Clin Vaccine Immunol. 2013 ;20:397-408.

Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips
A, Dunn DT; for the UK Collaborative Group on HIV Drug

Alfa-Wali M, Safarfashandi L, Ion L, Nelson M, Allen-Mersh T
& Bower M.

J Infect Dis. 2013 ;208(9):1459-63.

HIV Medicine 2013, 14 (suppl 2) 28

Revell AD, Alvarez-Uria G, Wang D, Pozniak A, Montaner JS,
Lane HC, Larder BA

Bull L, Bower M & Nelson M.

Persistence of HIV-1 Transmitted Drug Resistance

Potential Impact of a Free Online HIV Treatment
Response Prediction System for Reducing Virological
Failures and Drug Costs after Antiretroviral Therapy
Failure in a Resource-Limited Setting.
Biomed Res Int. 2013;2013:579741.

Cevik M, Dickinson L, Singh GS, Bower M & Nelson M

Raltegravir (RAL) switch improves hepatitis C
transaminitis in HIV-1 and hepatitis C (HCV) co-infected
HIV Medicine 2013, 14 (suppl 2) 71.

Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, SegalMaurer S, Bloch M, Garner W, Guy B, Williams S, Chuck S,
Vanveggel S, Deck H, Stevens M
Rilpivirine versus efavirenz in HIV1 infected subjects
receiving emtricitabine/Tenofovir DF: pooled 96 week
data from ECHO and THRIVE studies
HIV Clin Trials 2013 May-June; 14 (3): 81-91

Rayment M, Rae C, Ghooloo F, Doku E, Hardie J, Finlay S,
Gidwani S, Atkins M, Roberts P, Sullivan AK.
Routine HIV Testing in the Emergency Department:
Tough Lessons in Sustainability
HIV Med 2013; 14 Suppl 3:6-9

The HSV 040 Vaccine Study Group

Safety and Immunogenicity of a glycoprotein D genital
Herpes subunit vaccine in healthy 10-17 years of age.
Results from a randomised controlled double blind
Vaccine 2013 July 9. S0264-410X(13. 891-8


Salvage surgery for residual primary anal squamous
cell carcinoma after chemoradiotherapy in HIV-positive

Salvage therapy with protease inhibitor sparing
regimens containing etravirine
HIV Medicine 2013, 14 (suppl 2) 60.

Barber TJ, Bradshaw D, Hughes D, Leonidou L, Margetts
A, Ratcliffe D, Thornton S, Pozniak A, Asboe D, Mandalia S,
Boffito M, Davies N, Gazzard B, Catalan J.

Screening for HIV-related neurocognitive impairment in
clinical practice: Challenges and opportunities.
AIDS Care. 2013 Jul 22

Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C,
Fearnhill E, Dunn D, Phillips A; UK CHIC Study; UK HIV Drug
Resustance Database.
Second-line protease inhibitor-based antiretroviral
therapy after non-nucleoside reverse transcriptase
inhibitor failure: the effect of a nucleoside backbone.
Antivir Ther. 2013;18(2):213-9

Abdul-Latif M, Beckett H, Rayment M, Singh GKJ, Bower M
& Nelson M.
Shigella Flexneri enteritis in risk-taking HIV-infected
MSM – a single institution experience
HIV Medicine 2013, 14 (suppl 2) 76.

Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D,
Mohabeer M, Gazzard B, Boffito M

Tenofovir, emtricitabine intracellular and plasma, and
efavirenz plasma concentration decay following drug
intake cessation: implications for HIV treatment and
J Acquir Immune Defic Syndr. 2013;62:275-81



Samuel M, Jose S, Winston Am Nelson m, Johnson M,
Chadwick D, Fisher M, Leen C, Gomples M, Gilson R, Post F,
Hay P, Sabin C (UK CHIC)
The effects of age on associations between markers
of HIV progression and markers of metabolic
function including albumin, haemoglobulin and lipid
HIV Med 2013 Nov 19 doi: 10.1111

Mletzko S, Rai A, Westrop S, Imami N, Shahrabi Y, Della Pria
A, Howell S, Jones M, Gotch F & Bower M
The role of interleukin-6 and Interleukin-6 receptor
in multicentric Castleman’s disease: Frequency of
HIV Medicine 2013, 14 (suppl 2) 26

Della Pria A, Flook M, Williams J, Goode E, Berg L, NewsomDavis T, Nelson M & Bower M
The spectrum of non-AIDS defining malignancy: 431
HIV Medicine 2013, 14 (suppl 2) 27

Chamberlain FE, Chacko L, Singh GKJ, Bower M
& Nelson M

The use of azathioprine in HIV-infected individuals
HIV Medicine 2013, 14 (suppl 2) 65

Vishwanath V, Singh GKJ, Dub S, Bower M & Nelson M

The use of dual maraviroc/ritonavir boosted daraunavir
combination in clinical practice
HIV Medicine 2013, 14 (suppl 2) 59

Constandinou T, Vekeria S, Singh GKJ, Bower M & Nelson M
Use of antacid preparations with HAART
HIV Medicine 2013, 14 (suppl 2) 5

Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D,
Cummins N, Dalmau D, Dehovitz J, Lehmann C, Sullivan A,
Woolley I, Kuller L, Neaton JD, Tracy RP; INSIGHT SMART
Study Team.
HIV Replication Alters the Composition of Extrinsic
Pathway Coagulation Factors and Increases Thrombin
J Am Heart Assoc 2013; 2(4):e000264

Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A,
Salvato P, Bogner JR, Hay P, Santos J, Astier L, Pans M,
Balogh A, Biguenet S; the ReAL Study Team.

A randomized comparative 96-week trial of boosted
atazanavir versus continued boosted protease inhibitor
in HIV-1 patients with abdominal adiposity.
Antivir Ther. 2012. [Epub ahead of print]

Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ,
Conway B, Tobias JK, Vanhove GF; For the NGX-4010 C119
Study Group
A Randomized, Double-Blind, Controlled Study of
NGX-4010, a Capsaicin 8% Dermal Patch, for the
Treatment of Painful HIV-Associated Distal Sensory
J Acquir Immune Defic Syndr. 2012;59:126-133

Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG,

Are long-term non-progressors very slow progressors?
Insights form the Chelsea & Westminster HIV cohort
PLoS One 2012; 7 (2): e29844

Barber T, Bansi L, Leonidou L, Pozniak A, Asboe D, Nelson
M, Moyle G, Boffito M, Davies N, Thornton S, Catalan J,
Gazzard B
Baseline data from the MSM Neurocog study
J Int AIDS Soc. 2012 ;15:18176.

Ahmed A, Page E, Bower M & Nelson M.

Bocepravir for the treatment of chronic hepatitis C in
HIV co-infected.
HIV Medicine 2012, 13 (suppl 1) 41

Scourfield A, Waters L, Martin T, Mandalia S, Bower M,
Gazzard B & Nelson M.
Can antiretrovirals increase the risk of venous
thromboembolism in HIV infection?
HIV Medicine 2012, 13 (suppl 1) 56.

Awoyemi D, Mandalia S, Bower M, Anderson M & Nelson M
Can haemoglobin drop replace rapid virological
response in predicting a sustained virological
HIV Medicine 2012, 13 (suppl 1) 44.


Westrop SJ, Moyle G, Jackson A, Nelson M, Mandalia S,
Imami N.

Waters L, Patterson B, Scourfield A, Hughes A, de Silva S,
Gazzard B, Barton S, Asboe D, Pozniak A, Boffito M

A dedicated clinic for HIV-positive individuals over 50
years of age: a multidisciplinary experience

CCR5 antagonism impacts vaccination response and
immune profile in HIV-1 infection.
Mol Med. 2012;18:1240-8

Int J STD AIDS. 2012;23:546-52




2012 continued
Clutterbuck DJ, Flowers P, Barber T, Wilson H, Nelson M,
Hedge B, Kapp S, Fakoya A, Sullivan AK
Clinical Effectiveness Group of British Association
fro Sexual Health and HIV (BASHH) and British HIV
Association (BHIVA)
Int J STD AIDS. 20012 June; 23 (6): 38108

McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D,
McGrath D, Farajallah A, Moyle G.

Scourfield A, Zheng J, Chinthapall S, Waters L, Martin T,
Mandalia S, Nelson M

Discontinuation of Atripla as first-line therapy in HIV-1
infected individuals
AIDS: 2012 Jul 17; 26 (22): 1399-401

Lamorde M, Byakika-Kibwika P, Tamale WS, Kiweewa F, Ryan
M, Amara A, Tjia J, Back D, Khoo S, Boffito M, Kityo C,
Merry C.
Effect of Food on the Steady-State Pharmacokinetics of
Tenofovir and Emtricitabine plus Efavirenz in Ugandan

Clinical Significance of Hyperbilirubinemia Among HIV1-Infected Patients Treated with Atazanavir/Ritonavir
Through 96 Weeks in the CASTLE Study.

AIDS Res Treat. 2012;105980.

Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM,
Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD,
Winston A

Efficacy and safety of rilpivirine in treatment naïve.
HIV-1 infected patients with hepatitis B virus/hepatitis C
virus coinfections enrolled in the Phase III randomised,
double blind ECHO and THRIVE trials

AIDS Patient Care STDS. 2012;26:259-64

CNS effects of CCR% inhibitor in HIV infected subjects:
a pharmacokinetic and cerebral metabolite study
J Antimicrob Chemother. 2012 Jan; 67 (1); 206-12

Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabvin C, Post FA;
UK CHIC/CKD* Study Group

Comparison of CKD-EPI and MDRD to estimate baseline
renal function in HIV positive patients
Nephrol Dial Transplant. 2012 June; 27 (6): 2291-7

Westrop S, Mandalia S, Moyle G, Bower M, Nelson M
& Imami

Compounded Influence of Patient Age, ART Duration
and Time since HIV-1+ Diagnosis Delineates the
Immune Profile of the Ageing Cohort
N. CROI 2012

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I,
Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K,
Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe
D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration
in Chain
Declining prevalence of HIV-1 drug resistance in
antiretroviral treatment-exposed individuals in Western
Int J STD AIDS. 2012 Aug;23(8):546-52.

Chinthapalli S, Mandalia S, Jones R, Bower M & Nelson M.
Descriptive case series of eight HIV positive patients
with foot stress fractures.
HIV Medicine 2012, 13 (suppl 1) 55

Nelson M, Amaya G, Clumeck N, Arns da Cunha C,
Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A,
Vanveggel S, Boven K; ECHO and THRIVE Study Groups.

J Antomicrob Chemother. 2012 Aug; 67 (*): 2020-8

Schipani A, Egan D, Dickinson L, Davies G, Boffito M, Youle
M, Khoo SH, Back DJ, Owen A.
Estimation of the effect of SLCO1B1 polymorphisms
on lopinavir plasma concentration in HIV-infected
Antivir Ther. 2012;17:861-8

Thornton A, Rayment M, Mandalia S, Elam G, Atkins M,
Jones R, Nardone A, Roberts P, Tenant-Flowers M, Anderson
J, Sullivan A.
Exploring staff attitudes to routine HIV testing in
non-traditional settings: a qualitative study in four
healthcare facilities.
Sex Transm Infect 2012 ;88:601-6

Mletzko S, Shahrabi Y, Hislop A, Harding V, Nelson M, Gotch
F & Bower M.
Ex-vivo recognition of immediate-early T cell epitopes
within open reading frame ORF50 and K8 of Kaposi’s
sarcoma-associated herpesvirus (KSHV) by HIV/KSHVcoinfected individuals
HIV Medicine 2012, 13 (suppl 1) 32.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson
R, Bansi L, Pillay D, Dunn D; on behalf of the UK HIV Drug
Resistance Database and the UK Collaborative HIV Cohort
(UK CHIC) Study Steering Committees.
Frequency and patterns of protease gene resistance
mutations in HIV-infected patients treated with
lopinavir/ritonavir as their first protease inhibitor.
J Antimicrob Chemother. 2012 Apr;67(4):995-1000




Manley J, Dunning J, Nelson M, Bower M

HIV associated gastric natural killer? T-cell lymphoma
Int J STD AIDS 2012. Jan; 23 (1): 66-7

Rayment M, Thornton A, Mandalia S, Elam G, Atkins M, Jone
R, Nardone A, Roberts P, Tenant-Flowers M, Anderson J,
Sullivan A.
HIV Testing in Non-Traditional Settings - The HINTS
Study: A Multi-Centre Observational Study of Feasibility
and Acceptability
PLoS One 2012; 7(6):e39530. Epub 2012 Jun 22
Bashford J, Atkins M, Bower M & Nelson M.

How commonly is JC virus detected in the cerebrospinal
fluid of patients with HIV?
HIV Medicine 2012, 13 (suppl 1) 47

Vogel M, Page E, Boesecke C, Reiberger T, SchwarzeZander C, Mauss S, Baumgarten A, Wasmuth JC, Nelson M,
Rockstroph JK, European AIDS Treatment Network (NEAT)
Study Group
Liver fibrosis progression after acute hepatitis C virus
infection in HIV-positive individuals
Clin Infect Dis,. 2012 Feb 12; 54 (4): 556-9

Vrouenraets SM, Wit FW, Garcia EF, Huber M, Brinkman
K, Moyle G, Domingo P, Tarr PE, Podzamczer D, Ristola M,
Gatell JM, Livrozet JM, Furrer H, Reiss P; PREPARE Study
Longer prior exposure to zidovudine/lamivudinecontaining combination antiretroviral therapy, age,
and male gender are each associated with reduced
subcutaneous adipose tissue.
HIV Clin Trials. 2012;13:103-10.

Beck EJ, Mandalia S, Sangha R, Youle M, Brettle R, Gompels
M, Johnson M, Pozniak A, Schwenk A, Taylor S, Walsh
J, Wilkins E, Williams I, Gazzard B; NPMS-HHC Steering

SW Worm, M Bower, P Reiss, A Grulich,, E Fontas, F Bonnet,
G Faetkenheuer, M Law, A Phillips, HJ Furrer, W El-Sadr,
O Kirk, L Ryom, D Abrams, A D’Arminio Monforte, S De
Wit, C Sabin, JD Lundgren on behalf of the D:A:D study
Non-AIDS defining malignancies (NADM) and
immunosuppression: The D:A:D study
CROI 2012

Garlassi E, Harding V, Allen H, Allin B, Lee N, Nelson M &
Bower M.
Non-melanoma skin cancers among HIV-infected
persons in the HAART-era
HIV Medicine 2012, 13 (suppl 1) 34

Kober C, Johnson M, Fisher M, Hill, T Anderson J, Bansi L,
Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R,
Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth
J, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC)
Non-uptake of highly active antiretroviral therapy
among patients with a CD4 count <350 cells ul in the
HIV Med 2012 Jan; 13 (1); 73-8

Bradshaw D, Pallawela S, Nelson M, Scott C, Day C
Otosyphilis: missed opportunities for early
Sex Transm Infect. 2012 Sept 21

Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M,
Goodier MR
PD-1 Expression on Natural Killers Cells and CD8 (+) T
Cells During Chronic HIV-1 Infection
Viral Immunol. 2012 Aug; 25 (4): 329-32

Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C,
Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D

Lower healthcare costs associated with the use of a
single-pill ARV regimen in the UK, 2004-2008.

Pharmacokinetic and pharmacodynamic analysis of
efavirenz dose reduction using an in vitro-in vivo
extrapolation model

Salvinia Mletzko, Y Shahrabi, M Bower, K Hayward, V Harding, C Boshoff, A Benlahrech, and F Gotch.

Jackson A, Moyle G, Dickinson L, Back D, Khoo S, Taylor J,
Gedela K, Abongomera G, Gazzard B, Boffito M.

CROI 2012

Antivir Ther. 2012;17:19-24.

PLoS One. 2012;7(10):e47376

Modification of Dendritic Cell Function by Kaposi’s
Sarcoma-associated Herpesvirus Suggests a Novel
Immune Evasion Strategy

Clin Pharmacol Ther. 2012;92:494-502.

Pharmacokinetics of abacavir and its anabolite carbovir
triphosphate without and with darunavir/ritonavir or
raltegravir in HIV-infected subjects.




2012 continued
Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely
M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF,
Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger
M, Csajka C; Swiss HIV Cohort Study Group
Population pharmacokinetic analysis and
pharmacogenetics of raltegravir in HIV-positive and
healthy individuals.
Antimicrob Agents Chemother. 2012;56:2959-66.
Tan J, Sonali S, Bower M, Smith B & Nelson M

Reasons for non-utilisation of a home delivery service
among patients stabilised on antiretroviral therapy at 3
outpatient clinic sites

Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N.

The Effect of a 12-Week Course of Omega-3
Polyunsaturated Fatty Acids on Lipid Parameters in
Hypertriglyceridemic Adult HIV-infected Patients
Undergoing HAART: A Randomized, Placebo-Controlled
Pilot Trial.
Clin Ther. 2012;34:67-76

Carr A, Hoy J, Pozniak A.

The ethics of switch/simplify in antiretroviral trials: noninferior or just inferior?
PLoS Med. 2012;9(7):e1001240.

Thomas Newsom-Davis, Paul Fox, Victoria Bradley, Alessia
Dalla Pria, Mark Nelson, Mark Bower

HIV Medicine 2012, 13 (suppl 1) 19.

The features and outcome of HIV-associated anal cancer
in screened and unscreened populations

Fakoya I, Johnson AM, Fenton K, Anderson J, Nwokolo N,
Sullivan AK, Munday P, Burns FM

Shavadia J, Shah R, Yonga G, Patel R, Stebbing J, Nelson M

Religion and HIV diagnosis among Africans living in
HIV Med 2012; 13:617-22

Myers J, Rayment M, Sonecha S, Moyle G, Boffito M.

Room for manoeuvre when prescribing statins to
dyslipidaemic patients on antiretroviral therapy.
HIV Med. 2012;13(3):190-2.

Kumar N, Bower M, Nelson M

Severe vitamin D deficiency in a patient treated for
hepatitis B with tenofovir
Int J STD AIDS 2012. Jan; 23 (1): 59-60

Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back
D, Khoo S, Davies G
Simultaneous population pharmacokinetic modelling
of atazanavir and ritonavir in HIV-infected adults and
assessment of different dose reduction strategies
J Acquir Immune Defic Syndr. 2012;62:60-6

Lamorde M, Byakika-Kibwika P, Boffito M, Nabukeera L,
Mayito J, Ogwal-Okeng J, Tjia J, Back D, Khoo S, Ryan M,
Merry C
Steady-state pharmacokinetics of lopinavir plus
ritonavir when administered under different meal
conditions in HIV-infected Ugandan adults
J Acquir Immune Defic Syndr. 2012;60:295-8

J Clin Oncol 30, 2012 (suppl; abstr e14574

The influence of antiretroviral therapy on QTc interval in
an African cohort
Clin Infect Dis. 2012 Feb 1; 54 (3): 448-9

Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y,

The MONET trial: week 144 analysis of the efficacy of
darunavir/ritonavir DRV/r) monotherapy versus DRV/r
plus two nucleoside reverse transcriptase inhibitors
for patients with viral load <50 HIV-1 RNA copies/Ml at
HIV Med. 2012 Aug; 13 (7): 398-405

UK Collaborative Group on HIV Drug Resistance, Dolling
D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown
AL, Churchill D, Williams I, Geretti AM, Phillips A, Mackie N,
Murphy G, Castro H, Pillay D, Cane P, Dunn D, Dolling D.

Time trends in drug resistant HIV-1 infections in the
United Kingdom up to 2009: multicentre observational
BMJ. 2012 Aug 21;345:e5253

S. Kassam, M. Bower, S.M. Lee, J. De Vos, P. Fields, S.
Gandhi, M. Nelson, S. Montoto, M. Tenant-Flowers, F. Burns,
R. Marcus, S.G. Edwards, K. Cwynarski,
Treatment intensification for HIV-positive patients
with high-risk diffuse large B-cell lymphoma does not
improve outcome: a retrospective, multi-centre study
EHA 2012

Clutterbuck D, Flowers P, Barber T, Wilson H, Nelson M,
Hedge B, Kapp S, Fakoya A, Sullivan AK
UK national guideline on safer sex advice

International Journal of STD & AIDS 2012; 23




Caseiro MM, Nelson M, Diaz RS, Gathe J, de Andrade Neto
JL, Slim J, Solano A, Netto EM, Mak C, Shen J, Greaves W,
Dunkle LM, Vichez RA, Zeinecker J

Vicriviroc plus optimised background therapy for
treatment –experienced subjects with CCR5 HIV-1
infection: Final results of two randomised phase III trials
J Infect. 2012 OCT; 65 (4): 326-35 2012

Chemoradiotherapy of anal cancer in HIV patients
causes prolonged CD4 cell count suppression.
HIV Medicine 2011, 12 (Suppl 1), 7. 2011

S. Merchant, B. Lee, M. Nelson, T. Newsom-Davis, K. Naresh,
B. Gazzard, M. Bower
Clinical features and outcome in 61 patients with HIVassociated multicentric Castleman’s disease.


6th IAS Conference on HI pathogenesis, treatment and prevention (Rome) 2011.

V Tittle, C Fernandez, A Scourfield, B Gazzard, M Bower and
M Nelson.

A comparison of inpatient admissions in 2005 and 2010
at a tertiary centre
HIV Medicine 2011, 12 (Suppl 1), 68.

J Krell, T Newsom-Davis, M Bower, J Stebbing and M

Coinfection with hepatitis B virus does not increase the
risk of HIV-associated non-Hodgkin lymphoma
HIV Medicine 2011, 12 (Suppl 1), 37.

S Westrop, G D’Souza, M Bower, B Gazzard, M Nelson and
N Imami
Algorithmic prediction for the identification of novel
HLA-B*2705-restricted HIV-1 CD8 T-cell epitopes:
assessment of epitope stability, affinity and specific
T-cell profile
HIV Medicine 2011, 12 (Suppl 1), 29.

A Scourfield, A Jackson, L Waters, J Dunning, S de Silva, N
Francis, P Holmes, M Nelson and M Bower.
An atypical presentation of Kaposi’s sarcoma.
HIV Medicine 2011, 12 (Suppl 1), 39.

D Awoyemi, B Gazzard, M Bower, S Yau and M Nelson
Antiretroviral drug dosing in renal impairment
HIV Medicine 2011, 12 (Suppl 1), 54

A Scourfield, L Waters, V Tittle, T Martin, N Rockwood, B
Gazzard, M Bower and M Nelson

Azathioprine use as a novel treatment for cryptococcal
immune reconstitution and inflammatory syndrome in
HIV Medicine 2011, 12 (Suppl 1), 45.

Byakika-Kibwika P, Lamorde M, Lwabi P, Nyakoojo WB,
Okaba-Kayom V, Mayanja-Kizza H, Boffito M, Katabira E,
Back D, Khoo S, Merry C

Cardiac Conduction Safety during Coadministration of
Artemether-Lumefantrine and Lopinavir/Ritonavir in
HIV-Infected Ugandan Adults
Chemother Res Pract. 2011;393976

M Alfa-Wali, T Allen-Mersh, A Antoniou, D Tait, T NewsomDavis, B Gazzard, M Nelson and M Bower

S Merchant, V Bradley, M Mak, B Gazzard, M Nelson, M
Bower and T Newsom-Davis

Demographics, histology and survival in HIV-associated
lung cancer
HIV Medicine 2011, 12 (Suppl 1), 37

Mounier N, Bower M, Spina M, Besson C, Schiantarelli C, Re
A, Bonnet F, Hentrich M, Schommers P, Van Den Neste E,
Costagliola D, Borsatti E and Tirelli U.
Early determination of treatment sensitivity in HIVrelated Hodgkin lymphoma by FDG-PET/CT after two
cycles of ABVD chemotherapy

GECAT (European Cooperative Study Group on AIDS and
Tumors). Third international workshop on interim-PET in
lymphoma, Menton, France 2011
S Merchant, A Marouf, V Bradley, J Myers, T Newsom-Davis,
M Nelson, B Gazzard and M Bower.
Effect of raltegravir on rates of chemotherapy-induced
neutropenia in HIV lymphomas
HIV Medicine 2011, 12 (Suppl 1), 36.

R Robey, S Mletzko, M Bower, R Meys, M Boffito, M Nelson,S
Merchant, B Gazzard, C Boshoff and F Gotch
Ex-vivo recognition of late-lytic CD8 epitopes specific
for Kaposi’s sarcoma-associated herpesvirus (KSHV) by
HIV/KSHV-coinfected individuals
HIV Medicine 2011, 12 (Suppl 1), 23.

Merchant S, Marouf A, Hachach-Haram N, Nelson M, Bower
M and Newsom-Davis T
Histopathological trends in HIV-associated lung cancer
Lung Cancer 2011; 71(S1), 11




2011 continued
S Montoto, K Shaw, J Okosun, S Gandhi, P Fields, A Wilson,
M Shanyinde, K Cwynarski, R Marcus, J de Vos, AM Young,
M Tenant-Flowers, C Orkin, M Johnson, D Chilton, J
Gribben, M Bow

HIV Status Does Not Impact on Outcome in Patients with
Hodgkin Lymphoma Treated with ABVD Chemotherapy
in the HAART Era
Proc American Society of Haematology 2011.

Michael Furman, Pascual Balsalobre, Brady E. Beltran,
Michele Bibas, Mark Bower, Weina Chen, Silvia Montoto,
Roberto N. Miranda, Nahid M. Nanaji, Jose-Tomas
Navarro, Adam C. Seegmiller, Julie M. Vose and Jorge J
HIV-Associated Plasmablastic Lymphoma: A MultiInstitutional Study
Proc American Society of Haematology 2011.

E Page, M Bower, D Kaplan, J Daruich, L Kikuchi, M Marques
Molero, D Rimland, M Goetz, J Pineda8, K Marks, N Brau
and M Nelson

HIV-infected patients with hepatocellular carcinoma live
longer if they have undetectable HIV RNA.
HIV Medicine 2011, 12 (Suppl 1), 7. 2011

K Shahabuddin, R Mehta, S Graeme-Baker, H Gay, C Davies,
N Khan, F Kazmi, B Gazzard, M Bower and M Nelson.
Imaging of anorectal pathology by MR in people with
HIV infection
HIV Medicine 2011, 12 (Suppl 1), 38

S Mletzko, A Kyriakou, R Robey, M Bower, M Nelson, S
Merchant, B Gazzard, C Boshoff and F Gotch

Bulteel N, Bower M, Gazzard B, Mandalia S, Nelson M
Is emtricitabine associated with reduced levels
of the M184V mutation when compared with
13th European AIDS Conference, Belgrade 2011

L Baber, S Sonecha, S Mandalia, M Bower, B Gazzard and M
Patients’ willingness to switch from a single-tablet
regimen (STR) to individual drugs as part of a potential
cost-saving strategy
HIV Medicine 2011, 12 (Suppl 1), 80.

Letang E, Lewis J, Bower M, Mosam A, Borok M, Naniche D,
Newsom-Davis T, Shaik F, Campbell T and Easterbrook P.
Predictors of paradoxical IRIS associated with Kaposi’s
sarcoma in Sub-Saharan Africa and the UK: Developing
a predictive score

18th conference on retroviruses and opportunistic infections
(CROI) 2011, 417.
Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, Baily
G, Brettle R, Gompels M, Johnson M, McCarron B, Ong E,
Pozniak A, Schwenk A, Taylor S, Walsh J, Wilkins E, Williams
I, Gazzard B; NPMS-HHC Steering Group.
The cost-effectiveness of early access to HIV services
and starting cART in the UK 1996-2008.
PLoS One. 2011;6(12

B Lee, S Merchant, A Sita-Lumsden, B Gazzard, M Nelson
and M Bower

The incidence and correlates of paraneoplastic
syndromes in 62 HIV-positive patients with Hodgkin’s
HIV Medicine 2011, 12 (Suppl 1), 37.

Impaired dendritic cell (DC) function in Kaposi’s
sarcoma-associated herpesvirus (KSHV) infections.

K. Wheatley, J. Roe, M. Nelson, T. Newsom-Davis, B.
Gazzard, M. Bower.

S Westrop, D Lagos, M Bower, F Gotch, B Gazzard, C
Boshoff and N Imami

6th IAS Conference on HI pathogenesis, treatment and prevention (Rome) 2011.

HIV Medicine 2011, 12 (Suppl 1), 28.

Increased incidence of multicentric Castleman’s disease
in KSHV+ HIV-1+ individuals of Black African ethnicity
may result from the higher frequency of the TLR4 single
nucleotide polymorphism A299G.

The safety of Rituximab in HIV non-Hodgkin lymphoma
patients with low CD4 cell counts

J Roe, K Wheatley, T Kordbacheh, T Newsom-Davis, B
Gazzard, M Nelson and M Bower.

HIV Medicine 2011, 12 (Suppl 1), 6.

The safety of rituximab in patients with low CD4 cell

Okusun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus
R, Virchis A, McNamara C, Bower M & Cwynarski K.

A Scourfield, T Martin, N Rockwood, L Waters, S de Silva, P
Holmes, M Bower, B Gazzard and M Nelson.

Interim FDG-PET predicts response and progression free
survival in patients with Hodgkin lymphoma and HIV
Proc European Haematology Association. 2001 A774.


HIV Medicine 2011, 12 (Suppl 1), 36.

The use of faecal elastase to screen for pancreatic
insufficiency in HIV-infected individuals
HIV Medicine 2011, 12 (Suppl 1), 53



A Scourfield, L Waters, T Martin, N Rockwood, M Bower, M
Nelson and B Gazzard.

Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns
B, Pillay D, Nelson M.

HIV Medicine 2011, 12 (Suppl 1), 62.

Antiviral Res. 2010 May;86(2):224-6

Will earlier diagnosis of HIV reduce the presentation of
serious opportunistic infections?

Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, Manhard K,
Sheedy B, Hingorani V, Raney A, Nguyen M, Nguyen T, Ong
V, Yeh LT, Quart B.
A Phase 2a randomized controlled trial of the short
term activity, safety and pharmacokinetics of a novel
NNRTI, RDEA806 in HIV-1 positive, antiretroviral-naive
Antimicrob Agents Chemother. 2010 May 24.

Teague A, Scott C, Bower M, Gazzard B, Nelson M, Stebbing
A single-center cohort experience of raltegravir in
salvage patients failing therapy.
J Acquir Immune Defic Syndr. 2010 Apr;53(5):666-7

Clinical outcome in resistant HIV-2 infection treated
with raltegravir and maraviroc.

Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J,
Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M,
Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker
A, Delpech V; on behalf of the UK Collaborative HIV Cohort
(UK CHIC) Study Group.
Data linkage reduces loss to follow-up in an
observational HIV cohort study.
J Clin Epidemiol. 2010 Mar 26.
Moyle G, Demasi R, Hill A.

Does earlier HIV RNA suppression provide long-term
AIDS 2010;24:1591-3

Falutz J, Mamputu J-C, Potvin D, Moyle G, Soulban G,
Loughrey H, Marsolais C, Turner R, Grinspoon S.

Effects of Tesamorelin (TH9507), a Growth HormoneReleasing Factor Analog, in Human Immunodeficiency
Virus-Infected Patients with Excess Abdominal
J Clin Endocrinol Metab 16 June 2010,

Gazzard B, Balkin A, Hill A.

Analysis of neuropsychiatric adverse events during
clinical trials of efavirenz in antiretroviral-naive patients:
a systematic review.
AIDS Rev. 2010 Apr-Jun;12(2):67-75.

Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C,
Fisher M, Gilleece Y, Gilson R, Freedman A, Kulasegaram R,
Agarwal K, Sabin C, Deacon-Adams C; BHIVA Viral Hepatitis
Working Group
British HIV Association guidelines for the management
of coinfection with HIV-1 and hepatitis B or C virus
HIV Med. 2010 Jan;11(1):1-30

Cooper V, Moyle G, Fisher M, Reilly G, JEwan J, Liu H.C,
Horne R for the SWEET group UK
Changes in adherence and patients’ perceptions
of treatment in a 48 week randomised study of
continuation of zidovudine/lamividine or switch to
tenofovir DF/emtricitabine, each with efavirenz.
AIDS Care 2010: in press

Page EE, Cox A, Atkins M, Nelson MR.

Clearance of hepatitis C virus RNA from serum in HIV/
hepatitis C virus coinfection indicates eradication from
peripheral blood mononuclear cells

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M,
Michaud SE, Berger D, Somero M, Moyle G, Brown S,
Martorell C, Turner R, Grinspoon S.

Effects of Tesamorelin, a Growth Hormone-Releasing
Factor, in HIV-Infected Patients With Abdominal Fat
Accumulation: A Randomized Placebo-Controlled Trial
With a Safety Extension.
J Acquir Immune Defic Syndr. 2010;53:311-22

Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo
SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT,
Vanveggel S, Boven K; TMC278-C204 Study Group.
Efficacy and safety of TMC278 in antiretroviralnaive HIV-1 patients: week 96 results of a phase IIb
randomized trial.
AIDS. 2010 Jan 2;24(1):55-65.

On I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B,
Nelson M, Stebbing J.
Epidemiology of herpes simplex virus types 2 and 1
amongst men who have sex with men (MSM) attending
sexual health clinics in England and Wales: implications
for HIV prevention and management
Eurosurveillance in press.

AIDS. 2010 Jun 1;24(9):1267-71




2010 continued
R Jones, A Menon-Johansson, AM Waters, AK Sullivan

eTriage – a novle, web-based triage and booking
service: enabling timely access to sexual health clinics
Int J STD & AIDS 2010;  21:30-33.

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara
C, Orkin C, Nelson M, Johnson M, Bower M, Cwynarski AK.
Excellent immunological recovery following CODOX-M/
IVAC, an effective intensive chemotherapy for HIVassociated Burkitt’s lymphoma.
AIDS. 2010 Mar 27;24(6):851-6

Ridha E, Cookson H, Devitt E, Nelson M.

Febrile neutropenia in a HIV positive individual postchemotherapy
J Clin Virol. 2010 May;48(1):2-5. Epub 2010 Feb 18

Alfa-Wali A, Antoniou A, Allen-Mersh T, Tekkis P, Tate D, Sita
Lumsden A, Nelson M & Bower M

HIV-associated colorectal cancer and the immunological
effects of treatment
HIV Medicine 2010, 11 (suppl 1), 58.

Wilson J, Devitt E, Rampling T, Namulema E, Bower M &
Nelson M

Increasing prevalence of pulmonary tuberculosis in HIVinfected individuals in Kampala, Uganda.
HIV Medicine 2010, 11 (suppl 1),

Menon-Johansson A.S, Cohen C.E., Jones R., Nwokolo N.,
McOwan A., Barton S.E. & Sullivan A.K

Revell AD, Wang D, Harrigan R, Hamers RL, Wensing AM,
Dewolf F, Nelson M, Geretti AM, Larder BA

Modelling response to HIV therapy without a genotype:
an argument for viral load monitoring in resourcelimited settings
J Antimicrob Chemother. 2010 Apr;65(4):605-7

McClean H, CA Carne, AK Sullivan, A Menon-Johansson, R
Gokhale, G Sethi, AG Mammen-Tobin, D Daniels.
National Audit of Asymptomatic Screening in UK
Genitourinary Medicine Clinics: Clinic Policies Audit.
Int J STD & AIDS in press

Rashid T, Meryon I, Mandalia S, Waters L, Devitt E, Bower M,
Jones R & Nelson M
No association of vitamin D levels with individual
antiretroviral agents, duration of HIV infection,
alkaline phosphatise levels or bone mineral density
HIV Medicine 2010, 11 (suppl 1), 34

Bower M, Montoto S, Cwynarski K, Sita Lumsden A, Rajab R,
Okosum J, Orkin C, Nelson M, Isaacson P, Calaminici M &
Naresh K
Non-germinal centre subtype of AIDS-related diffuse
large B-cell lymphomas associated with improved
HIV Medicine 2010, 11 (suppl 1), 13.

Kityo C, Walker AS, Dickinson L, Lutwama F, Kayiwa J, Ssali
F, Nalumenya R, Tumukunde D, Munderi P, Reid A, Gilks CF,
Gibb DM, Khoo S; DART Trial Team
Pharmacokinetics of lopinavir-ritonavir with and
without nonnucleoside reverse transcriptase inhibitors
in Ugandan HIV-infected adults.

Interventions to increase access to STI services: A study
of England’s‘High Impact Changes’ across three central
London clinics

Antimicrob Agents Chemother. 2010 Jul;54(7):2965-73.

Yilmaz S, Boffito M, Collot-Teixeira S, De Lorenzo F, Waters L,
Fletcher C, Back D, Pozniak A, Gazzard B, McGregor JL.

Positive and negative drug selection pressures on the
N3481 connection domain mutation: new insights from
in vivo data

STI 2010 in press

Investigation of low-dose ritonavir on human peripheral
blood mononuclear cells using gene expression whole
genome microarrays.

Price H, Asboe D, Gazzard B, Fearnhill E. Pillay D, Dunn
D: UK Collaborative Group on HIV Drug Resistance; UK
Collaborative HIV Cohort Study

Anitfir Ther. 2010: 15(2): 203-11.

Genomics. 2010 Jul;96(1):57-65. Epub 2010 Mar 28. 2010

Willis J, Jones R, Nwokolo N and Levy J

UK Collaborative Group on HIV Drug Resistance; UK CHIC
Study Group

BMJ 2010;340:b5027

Long-term probability of detecting drug-resistant HIV
in treatment-naive patients initiating combination
antiretroviral therapy

Protein and Creatine Supplements and Misdiagnosis of
Kidney Disease

Clin Infect Dis. 2010 May 1;50(9):1275-85.




Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D,
Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses
MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML.
Randomized Comparison of Renal Effects, Efficacy, and
Safety With Once-Daily Abacavir/Lamivudine Versus
Tenofovir/Emtricitabine, Administered With Efavirenz,
in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week
Results From the ASSERT Study
J Acquir Immune Defic Syndr. 2010 Apr 24.

Jones R, Brown D, Nelson M, Low E, Bhagani S, Atkins M,
Danta M, Dusheiko G, Pybus O, Asboe D.

Re-emergent hepatitis C viremia after apparent
clearance in HIV-positive men who have sex with men:
reinfection or late recurrence?

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):547-50. No
abstract available. Erratum in: J Acquir Immune Defic Syndr.
2010 May 1;54(1):112
Williams J, Jones R, Nelson M, Barlow S, Short D, Savage P,
Seckl M, Schmidt P & Bower M.
Six cases of gestational trophoblastic tumours in
women living with HIV.
HIV Medicine 2010, 11 (suppl 1), 60.

Scourfield A, Waters L, Brown G, Bower M & Nelson M.
Spectrum of neurological disease in patients
with discordant HIV-1 RNA levels in plasma and
cerebrospinal fluid.
HIV Medicine 2010, 11 (suppl 1), 34-5.
HIV-CAUSAL Collaboration

The effect of combined antiretroviral therapy on the
overall mortality of HIV-infected individuals
AIDS. 2010 Jan 2;24(1):123-37

Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ.

The effect of tenofovir disoproxil fumarate on wholebody insulin sensitivity, lipids and adipokines in healthy
Antivir Ther. 2010;15:227-33.

on I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B,
Nelson M, Stebbing J.
The frequency and reasons for antiretroviral switching
with specific antiretroviral associations: the SWITCH
Antiviral Res. 2010 May;86(2):227-9

Dunn D, von Wyl V, Price H, Asboe D.

The impact of the 0-0 cell on measures of amino acid

Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson
M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T,
Moecklinghoff C.

The MONET trial: darunavir/ritonavir with or without
nucleoside analogues, for patients with HIV RNA below
50 copies/ml
AIDS. 2010 Jan 16;24(2):223-30

Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet
M, Valantin MA, Katlama C, Rockstroh JK, Nelson M.
Treatment of acute HCV infection in HIV-positive
patients: experience from a multicentre European
Antivir Ther. 2010;15(2):267-79

Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J,
Chadborn T, Easterbrook P, Gilson R, Johnson M, Porter
K, Anderson J, Gompels M, Leen C, Ainsworth J, Orkin C,
Nelson M, Rice B, Phillips A; UK Collaborative HIV Cohort
(CHIC) Study and the Health Protection Agency
Trends over calendar time in antiretroviral treatment
success and failure in HIV clinic populations
HIV Med. 2010 Aug;11(7):432-8

Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M,
Heera J, Rajicic N, Goodrich J.

Two-Year Safety and Virologic Efficacy of Maraviroc in
Treatment-Experienced Patients With CCR5-Tropic HIV-1
Infection: 96-Week Combined Analysis of MOTIVATE 1
and 2.
J Acquir Immune Defic Syndr. 2010 Aug 11

Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D

Unselected hepatitis C screening of men who have sex
with men attending sexual health clinics
J Infect. 2010 May;60(5):351-3. Epub 2010 Feb 12.PMID:

Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A,
Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C,
Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E,
Dally L, Gotch F, Walker B, Gilmour J, Hayes P
Viral inhibition assay: a CD8 T cell neutralization assay
for use in clinical trials of HIV-1 vaccine candidates.
J Infect Dis. 2010 Mar;201(5):720-9 2010

Brown G, Scott C, Teague A, Bower M, Gazzard B
& Nelson M

Virological efficacy of darunavir/ritonavir monotherapy
in clinical practice
HIV Medicine 2010, 11 (suppl 1), 24

AIDS. 2010 Jan 2;24(1):159-60. No abstract available




Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR,
Mandalia S, Bower M, Gazzard B, Nelson M

A Meta-analysis of Transient Elastography for the
Detection of Hepatic Fibrosis
J Clin Gastroenterol. 2009 Sep 9.

Stebbing J, Scourfield A, Koh G, Taylor C, Taylor S, Wilkins E,
Gazzard B, Nelson M, Jones R.

Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ,
Sax P

Antiretroviral therapy update from the 48th ICAAC/46th
IDSA annual meeting
AIDS Read. 2009;19:22-31.

Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF,
Moyle GJ, Jackson AA, Gazzard BG.
Antiretroviral therapy with or without protease
inhibitors impairs postprandial TAG hydrolysis in HIVinfected men.

A multicentre cohort experience with double-boosted
protease inhibitors.

Br J Nutr. 2009 Jun 1:1-9.

Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M,
Wilkins E, Ewan J, Liu H, Ebrahimi R, Reilly G for the SWEET
(Simplification With Easier Emtricitabine Tenofovir) group

Burkitt’s non-Hodgkin lymphoa presenting as an
isolated Bell’s palsy in HIV-positive patients

J Antimicrob Chemother. 2009 Aug;64(2):434-5.

A Randomized Comparative Trial of Continued
Zidovudine/Lamivudine or Replacement With Tenofovir
Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated
HIV-1-Infected Individuals

Woodcock H, Holmes P, Powles S, Dunning J, Bower M &
Nelson M.

HIV Medicine 2009, 10 (Suppl1), 23 2009

Scott C, Azwa A, Cohen C, McIntyre M, Desmond N
Catscratch disease: a diagnostic conundrum
Int J STD AIDS. 2009 Aug; 20(8) 585-6

Journal of Acquired Immune Deficiency Syndromes.

Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey
D, Skoutelis A, Goetz MB, Phillips AN

HIV Clin Trials. 2009 Sep-Oct;10(5):289-98.

Activation and coagulation biomarkers are independent
predictors of the development of opportunistic disease
in patients with HIV infection.
J Infect Dis. 2009 Sep 15;200(6):973-83.

Holmes P, Low E, Bower M, Anderson M & Nelson M.

Acute hepatitis C is not associated with abnormal
fibroscan readings
HIV Medicine 2009, 10 (Suppl1), 30
Ng SC, Gazzard B.

Advances in sexually transmitted infections of the
gastrointestinal tract
Nat Rev Gastroenterol Hepatol. 2009 Aug 25

Powles S, Weir J, Francis N, Newsom-Davis T, Crook T,
Boffito M, Nelson M & Bower M.

AIDS Kaposi’s sarcoma: outcomes in 254 consecutive
patients diagnosed in modern times
HIV Medicine 2009, 10 (Suppl1), 10.

Causes and consequences of incomplete HIV RNA
suppression in clinical trials.

Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips
AN, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B,
Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels
M, Sabin CA
CD4 counts and the risk of systemic non-Hodgkin’s
lymphoma in individuals with HIV in the UK.
Haematologica. 2009 Jun;94(6):875-80

Teague A, Scott C, Bower M, Gazzard B & Nelson M.

Clinical experience of raltegravir in salvage patients
failing therapy, 48-week data
HIV Medicine 2009, 10 (Suppl1), 17

Moyle G, Rajicic N, Goodrich J, Mayer H, Valdez H.

Concurrent use of statins does not influence efficacy
of maraviroc in Maraviroc versus Optimized Therapy in
Viremic Antiretroviral Treatment-Experienced Patients 1
and 2 trials
AIDS 2009: 23:1613.

Walmsley S, Wilkin T, Moyle G

Antiretroviral rounds. Too many options?
AIDS Clin Care. 2009;21:13-5.




Panos G, Farouk L, Stebbing J, Holmes P, Valero S, Randell P,
Bower M, Gazzard B, Anderson M, Nelson M
Cryptogenic pseudocirrhosis: a new clinical syndrome
of noncirrhotic portal hypertension (unassociated with
advanced fibrosis) that can be detected by transient
elastography in patients with HIV
J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):525-7
Bower M, Veraitch O, Szydlo R, Charles P, Kelleher P,
Gazzard B, Nelson M, Stebbing J.

Cytokine changes during rituximab therapy in HIVassociated multicentric Castleman disease.
Blood. 2009 May 7;113(19):4521-4.

Scott C, Teague A, Bower M, Gazzard B & Nelson M

Darunavir/ritonavir once daily: a single-centre cohort
HIV Medicine 2009, 10 (Suppl1), 8
Soodalter J, Sousa M, Boffito M

Drug-drug interactions involving new antiretroviral
drugs and drug classes.
Curr Opin Infect Dis. 2009 Feb;22(1):18-27.

ScourfieldA, Waters L, Randell PA, McCormick K, Armenis K,
Bower M & Nelson M
Effect of raltegravir on ALT in subjects coinfected with
HIV and hepatitis C
HIV Medicine 2009, 10 (Suppl1), 31

Arastéh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D,
Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F.

Efficacy and safety of darunavir/ritonavir in treatmentexperienced HIV type-1 patients in the POWER 1, 2 and
3 trials at week 96.
Antivir Ther. 2009;14(6):859-64.

Wilson J, Montoto S, Shaw K, Orkin C, Johnson M, Nelson
M, Bower M & Cwynarski K.
Excellent immunological recovery following the
intensive chemotherapy CODOX-M IVAC, an effective
therapy for HIV associated Burkitt’s lymphoma.
HIV Medicine 2009, 10 (Suppl1), 5

Dunning J, Myers J, Holmes P, Stuart-Buttle C, Bower M &
Nelson M.
Experience with ritonavir/atazanavir in HIV-positive
antiretroviral naive individuals commencing therapy.
HIV Medicine 2009, 10 (Suppl1), 18
Hill A, Sawyer W, Gazzard B.

Fat: A Pooled Analysis of Two Multicenter, Double-Blind
Placebo-Controlled Phase 3 Trials with Safety Extension
HIV Clin Trials. 2009 Jan-Feb;10(1):1-12.

Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M,
O’Doherty M & Bower M.
FDG-PET/CT imaging in the management of HIVassociated multicentric Castleman’s disease
Eur J Nucl Med Imaging. 2009, 36: 648-52

Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V,
Bower M, Dezube BJ
Gastroenteropancreatic Neuroendocrine Tumors in
Patients With HIV Infection: A Trans-Atlantic Series.
Am J Med Sci. 2009 Jan;337(1):1-4.

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M,
Gazzard B, Mandelia S, Moller H & Bower M

Highly active antiretroviral therapy and the incidence of
Non-AIDS defining cancers in people with HIV infection
J Clin Oncol. 2009 Feb 20;27(6):884-90.

Pozniak A, Müller L, Salgo M, Jones JK, Larson P, Tweats D.

Price H, Sullivan AK

AIDS Res Ther. 2009 Aug 6;6:18.

Int J STD AIDS. 2009 Jan;20(1):56-7.

Elevated ethyl methanesulfonate (EMS) in nelfinavir
mesylate (Viracept, Roche): overview.

Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM &
Goodier MR.

Elevated plasma lipopolysaccharide is not sufficient
to drive natural killer cell activation in HIV-1 infected
AIDS 2009, 23: 29-34.

HIV opt out increases the offer and uptake of HIV tests
in a GUM clinic

Gazzard B.

HIV testing in the UK

Lancet. 2009 Aug 1;374(9687):377
Vogel M, Nelson M.

HIV/HCV-coinfection: which role can new antiretrovirals
such as integrase inhibitors play?
Eur J Med Res. 2009 Nov 24;14 Suppl 3:36-42. Review.




2009 continued
Herasimtschuk A, Nelson M, Moyle G, Bower M & Imani N

Impact of recombinant human growth hormone on
T-cell phenotype and function in vitro and in vivo during
treated HIV-1 infection.
HIV Medicine 2009, 10 (Suppl1), 5.

Benn P, Sauret-Jackson V, Cartledge J, Ruff C, Sabin CA,
Moyle G, Linney A, Reilly G, Edwards S.

Improvements in cheek volume in lipoatrophic
individuals switching away from thymidine nucleoside
reverse transcriptase inhibitors
HIV Medicine 2009;10:351-5

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy
R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT
SMART Study Group.

Interruption of antiretroviral therapy is associated with
increased plasma cystatin C
AIDS. 2009 Jan 2;23(1):71-82.

Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C,
Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay
D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips
A, Sabin C; on behalf of the UK Collaborative HIV Cohort
(CHIC) Study

Is 1 Alanine Transaminase >200 IU Enough to Define an
Alanine Transaminase Flare in HIV-Infected Populations?
A New Definition Derived From a Large Cohort Study.

Crook T, Syed N, Papoudou-Bai A, Stebbing J, Naresh K,
Nelson M, Hatzimichael E & Bower M

Methylation reversal in high grade B-cell lymphoma
cell lines identifies novel epigenetic changes conserved
between immunocompetent and HIV-positive hosts and
others specific to HIV-associated lymphomas.
HIV Medicine 2009, 10 (Suppl1), 4.

Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P,
Patterson S.

Monocyte-derived dendritic cells from HIV type
1-infected individuals show reduced ability to stimulate
T cells and have altered production of interleukin (IL)-12
and IL-10.
J Infect Dis. 2009 Jun 15;199(12):1862-71.
Dunning J, Nelson M.

Novel strategies to treat antiretroviral-naive HIVinfected patients.
J Antimicrob Chemother. 2009 Oct;64(4):674-9.


Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti
I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV,
Lavreys L
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir
in treatment-naive, HIV-1-infected patients: 96-week
AIDS. 2009 Aug 24;23(13):1679-88.

Sekar V, Lefebvre E, Mariën K, De Pauw M, Vangeneugden T,
Pozniak A, Hoetelmans RM.
Pharmacokinetic interaction between nevirapine and
darunavir with low-dose ritonavir in HIV-1-infected
Br J Clin Pharmacol. 2009 Jul;68(1):116-9.

Boffito M, Jackson A, Lamorde M, Back D, Watson V, Taylor
J, Waters L, Asboe D, Gazzard B, Pozniak A.

Pharmacokinetics and Safety of Etravirine Administered
Once or Twice Daily After 2 Weeks Treatment With
Efavirenz in Healthy Volunteers.
J Acquir Immune Defic Syndr. 2009 Jul 17

Coyne KM, Pozniak AL, Lamorde M, Boffito M

Pharmacology of second-line antituberculosis drugs
and potential for interactions with antiretroviral agents
AIDS. 2009 Feb 20;23(4):437-46.

Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G,
Khoo S, Pozniak A, Aarons L.
Population pharmacokinetics of ritonavir-boosted
atazanavir in HIV-infected patients and healthy

J Antimicrob Chemother. 2009 Jun;63(6):1233-43. Epub
2009 Mar 28
Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks
CB, Klein CE, Chiu YL, King MS, Bernstein BM.
Predictors of loss of virologic response in subjects who
simplified to lopinavir/ritonavir monotherapy from
lopinavir/ritonavir plus zidovudine/lamivudine.
AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75.

De Lorenzo F, Boffito M, Collot-Teixeira S, Gazzard B,
McGregor JL, Shotliff K, Xiao H.

Prevention of atherosclerosis in patients living with HIV.
Vasc Health Risk Manag. 2009;5(1):287-300.

Moyle G, Dejesus E, Boffito M, Wong RS, Gibney C, Badel
K, Macfarland R, Calandra G, Bridger G, Becker S; X4
Antagonist Concept Trial Study Team.
Proof of Activity with AMD11070, an Orally
Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1.
Clin Infect Dis. 2009;48:798-805.



Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett
PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M,
Cameron DW, Brown ST; OPTIMA Team1.

Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH,
Lou Y, Yuen GJ, Min SS, Guerini EM.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):631-9.

Antimicrob Agents Chemother. 2009;53:1532-8

Quality of life of patients with advanced HIV/AIDS:
measuring the impact of both AIDS-defining events and
non-AIDS serious adverse events.

Annan NT, Sullivan AK, Nori A, Naydenova P, Alexander
S, McKenna A, Azadian B, Mandalia S, Rossi M, Ward H,
Nwokolo N.

Rectal Chlamydia – a reservoir of undiagnosed infection
in men who have sex with men.
Sex Transm Infect 2009; 85:176-9.

Tan LK, Gilleece Y, Mandalia S, Murungi A, Grover D, Fisher
M, Atkins M, Nelson M.

Steady state pharmacokinetics of plasma abacavir and
intracellular carbovir triphosphate following abacavir
600mg once daily and 300g twice daily in HIV-infected

Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH,
Lou Y, Yuen GJ, Min SS, Guerini EM
Steady-state pharmacokinetics of abacavir in plasma
and intracellular carbovir triphosphate following
administration of abacavir at 600 milligrams once
daily and 300 milligrams twice daily in human
immunodeficiency virus-infected subjects.
Antimicrob Agents Chemother. 2009 Apr;53(4):1532-8

Reduced glomerular filtration rate but sustained
virologic response in HIV/hepatitis B co-infected
individuals on long-term tenofovir

Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W,
Pozniak A, Taylor G, Asboe D, Lyall H, Shaw A, Kapembwa M

Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ,
Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft
A; Nevirapine Toxicity Multicohort Collaboration.

AIDS. 2009 Jan 28;23(3):434-5. No abstract available

J Viral Hepat. 2009 Jul;16(7):471-8.

Risk factors for treatment-limiting toxicities in
patients starting nevirapine-containing antiretroviral
AIDS. 2009 Aug 24;23(13):1689-99

Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ,
Sax PE
Select updates from the 16th CROI: treatment-related
cardiovascular risk, pharmacokinetic issues, and
interleukin-2 use
AIDS Read. 2009;19:158-60.

Coyne KM, Banks A, Heggie C, Scott CJ, Grover D, Evans C,
Mandalia S, McLean KA, Cohen CE
Sexual health of adults working in pornographic films
Int J STD AIDS. 2009 Jul;20(7):508-9

Teague A, Scott C, Youngstein T, Bower M, Gazzard B &
Nelson M.

Switching to raltegravir: a successful strategy in
treatment-experienced patients with toxicity? 48 week
HIV Medicine 2009, 10 (Suppl1), 21.

Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson
R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher
M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK
Collaborative HIV Cohort (CHIC) Study.
The associations between age and the development of
laboratory abnormalities and treatment discontinuation
for reasons other than virological failure in the first year
of highly active antiretroviral therapy.
HIV Med. 2009 Jan;10(1):35-43. Epub 2008 Nov 10.

Bower M, Weir J, Francis N, Newsom-Davis T, Powles S,
Crook T, Boffito M, Gazzard B, Nelson M

Barton S

Sexually transmitted diseases by Dr Lisa Marr
AIDS Care. Vol 21. No. 4 April 2009

The effect of HAART in 254 consecutive patients with
AIDS-related Kaposi’s sarcoma.
AIDS. 2009, 23(13):1701-6.

Arastéh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van
Heeswijk R, de Béthune MP, Peeters M, Woodfall B.
Short-term randomized proof-of-principle trial of
TMC278 in patients with HIV type-1 who have
previously failed antiretroviral therapy.
Antivir Ther. 2009;14(5):713-22.

Successful use of darunavir, etravirine, enfuvirtide
and tenofovir/emtricitabine in pregnant woman with
multiclass HIV resistance

Coyne K, Mandalia S, McCullough S, Catalan J, Noestlinger
C, Colebunders R, Asboe D
The International Index of Erectile Function:
development of an adapted tool for use in HIV-positive
men who have sex with men.
J Sex Med. 2010 Feb;7(2 Pt 1):769-74. Epub 2009 Nov 12




2009 continued
Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG,
Stebbing J.
The Nucleoside Backbone Affects Durability of
Efavirenz- or Nevirapine-Based Highly Active
Antiretroviral Therapy in Antiretroviral-Naive

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):140-6.
Stebbing J, Wong N, Tan L, Scourfield A, Jiao L, Shousha S,
Grover D, Bower M, Nelson M
The relationship between prolonged antiretroviral
therapy and cryptogenic liver disease

J Acquir Immune Defic Syndr. 2009 Apr 1;50(5):554-6.
Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S,
Nelson M, Gazzard B, Bower M.

Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J,
Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M,
Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK
Collaborative HIV Cohort Study.
Virological response to initial antiretroviral regimens
containing abacavir or tenofovir.
J Infect Dis. 2009 Sep 1;200(5):710-4.

Gabriel I, Apperley J, Bower M, Chaidos A, Gazzard B, Giles
C, Kew A, Nelson M, Kanfer E.
A long-term durable remission with high-dose therapy
and autologous stem cell transplant for stage IVB HIVassociated Hodgkins disease
AIDS. 2008 Feb 19;22(4):539-40

The role of immune suppression and HHV-8 in the
increasing incidence of HIV-associated multicentric
Castleman’s disease.

Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ.

Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M,
Gazzard B & Stebbing J.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:54-9

Ann Oncol. 2009, 20:775-9.

Thyroid dysfunction and relationship to antiretroviral
therapy in HIV-positive individuals in the HAART era.
J Acquir Immune Defic Syndr. 2009, 50: 113-114.

Westrop SJ, Qazi NA, Pido-Lopez J, Nelson MR, Gazzard B,
Gotch FM, Imami N.
Transient nature of long-term nonprogression and
broad virus-specific proliferative T-cell responses with
sustained thymic output in HIV-1 controllers.
PLoS One. 2009;4(5):e5474

Vogel M, Page E, Nelson M, Rockstroh JK.

A novel probe drug interaction study to investigate the
effect of selected antiretroviral combinations on the
pharmacokinetics of a single oral dose of maraviroc in
HIV-positive subjects.

Boffito M, Abel S.

A review of the clinical pharmacology of maraviroc.
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:1-4

Scott C, Jogiya R, Teague A, Bower M, Gazzard B
& Nelson M

A single centre experience with darunavir/ritonavir
(DRV/r) (600mg/100mg) and optimised background
regimen in clinical practice
HIV Medicine 2008, 9 (Suppl 1): 14 2008

Treatment of acute hepatitis C in HIV-positive
individuals: what are the challenges?

Scott C, Staughton RC, Bunker CJ, Asboe D

A. Hughes, E. Jungmann, S. Manney, L. Muromba, N.
Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K.

Int J STD AIDS. 2008 Jul;19(7):493-5

J HIV Ther. 2009 Mar;14(1):8-12. Review

United Kingdom acquisition of HIV infection in African
residents in London: more than previously thought.
AIDS 2009; 23:262-6.

Stebbing J, Asghar AK, Holmes P, Bower M, Isenman HL &
Nelson M. J
Use of ezetimibe during HIV infection

Acne vulgaris and acne rosacea as part of immune
reconstitution disease in HIV-1 infected patients starting
antiretroviral therapy.

FM Burns, R Arthur, A Johnson, J Nazroo, K Fenton; on
behalf of the SONHIA collaboration group J. Ainsworth, J.
Anderson, M. Chikohora, A. Fakoya, I.Fakoya, A. Hughes,
E. Jungmann, S. Manney, L. Muromba, N. Nwokolo, N.
Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K. Sullivan
Acquisition of HIV infection in Africans resident in
London: how much and how to assess
AIDS 2008; in press

Antimicrob Chemother. 2009, 6: 43-52.




Di Lorenzo G, Kreuter A, Di Trolio R, Guarini A, Romano C,
Montesarchio V, Brockmeyer NH, De Placido S, Bower M,
Dezube BJ

Steel A, John L, Shamji MH, Henderson DC, Gotch FM,
Gazzard BG, Kelleher P.

J Invest Dermatol. 2008 Jan 10

HIV Med. 2008 Feb;9(2):118-25

Activity and Safety of Pegylated Liposomal Doxorubicin
as First-Line Therapy in the Treatment of Non-Visceral
Classic Kaposi’s Sarcoma: A Multicenter Study

Stebbing J, Powles T, Bower M

AIDS-associated Kaposi’s sarcoma associated with a low
viral load and a high CD4 cell count
AIDS. 2008; 22(4):551-2

Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T,
Leen C, Schwenk A, Johnson M, Anderson J, Gilson R,
Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay
D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV
Cohort (UK CHIC) Study
Are previous treatment interruptions associated
with higher viral rebound rates in patients with viral
AIDS. 2008 Jan 30;22(3):349-56.

J. Krell, M. Tuthill, V. Campbell, M. Nelson, P. Holmes, T.
Powles, J. Stebbing, M. Bower

Cellular immunity following chemotherapy for systemic
AIDS related non Hodgkin’s lymphoma (NHL)
HIV Medicine 2008, 9 (Suppl 1): 24. 2008

Teague A, Scott C, Youngstein T, Bower M, Gazzard B &
Nelson M

Clinical experience with raltegravir (MK-0518 or
Isentress), with an optimised background regimen in
highly treatment experienced patients
HIV Medicine 2008, 9 (Suppl 1): 17.

Holmes P, Nelson M, Bower M, Gazzard B & Barton S.

Coyne KM, Barton SE, Smith NA, Cohen CE

Azithromycin without a prescription increases access
and choice for patients
Int. J. STD & AIDS 2008;19:870

Bower M, Collins S, Cottrill C, Cwynarski K, Montoto
S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales
N & Webb A on behalf of the AIDS malignancy

British HIV association guidelines for HIV-associated
malignancies 2008.
HIV Med 2008, 9: 336-388 2008

Coding and the clinician.

HIV Medicine 2008, 9 (Suppl 1): 46.
Daniels RH, Gazzard BG, Holmes P, Scourfield A, Bower M,
Nelson M
Comparing the efficacy of Truvada® and Kivexa®
combination therapy in HAART-naive individuals with
different viral loads.
Journal of the International AIDS Society 2008, 11 (Suppl
1):P14 (10 November 2008)
Gazzard BG.

Controversies in current treatment guidelines.

Gazzard BG; BHIVA Treatment Guidelines Writing Group
British HIV Association Guidelines for the treatment
of HIV-1-infected adults with antiretroviral therapy
HIV Med. 2008 Oct;9(8):563-608.

Stebbing J, Wood C, Atkins M, Bukowski R, Litwin S, Bower
M, Parsa A, Levitsky H
Cancer vaccines: Clinical development challenges and
proposed regulatory approaches for patient access to
promising treatments
Cancer. 2008;112(5):955-961

CD38 expression on CD8 T cells has a weak association
with CD4 T-cell recovery and is a poor marker of viral
replication in HIV-1-infected patients on antiretroviral

J HIV Ther. 2008 Mar;13(1):1-3.

Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A,
Miller MD, Emery S, van Leth F, Robinson P, Baxter JD, PerezElias M, Castor D, Hammer S, Rinehart A, Vermeiren H, Van
Craenenbroeck E, Bacheler L.
Determination of clinically relevant cutoffs for HIV-1
phenotypic resistance estimates through a combined
analysis of clinical trial and cohort data.
J Acquir Immune Defic Syndr. 2008 May 1;48(1):26-34.

Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A,
van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD;
EuroSIDA Study Group.
Does less frequent routine monitoring of patients on
a stable, fully suppressed cART regimen lead to an
increased risk of treatment failure?
AIDS. 2008 Nov 12;22(17):2381-90.




2008 continued
Mihailidis C, Dunn D, Pillay D, Pozniak A

Effect of isolated V118I mutation in reverse
transcriptase on response to first-line antiretroviral
AIDS. 2008 Jan 30;22(3):427-30

Rosignoli G, Liptrott N, Imani N, Bower M, Gotch F
& Owen A

Effect of PD1.3 single nucleotide polymorphism on CD4
and CD3 T cell counts in HAART-treated chronic HIV-1+
HIV Medicine 2008, 9 (Suppl 1): 8.

Schöller-Gyüre M, Boffito M, Pozniak AL, Leemans R, Kakuda
TN, Woodfall B, Vyncke V, Peeters M, Vandermeulen K,
Hoetelmans RM.

Scott C, Khatib N, Bower M, Gazzard BG, Nelson M.

Etravirine use in clinical practice: 48-week data from a
single centre cohort.
Journal of the International AIDS Society 2008, 11(Suppl
1):P49 (10 November 2008)

Clumeck N, Pozniak A, Raffi F; EACS Executive Committee.

European AIDS Clinical Society (EACS) guidelines for
the clinical management and treatment of HIV-infected
HIV Med. 2008 Feb;9(2):65-71

Asghar AK, Bower M, Holmes P, Gazzard BG, Isenman H,
Nelson M
Ezetimibe as lipid-lowering therapy for patients
receiving HAART.

Journal of the International AIDS Society 2008, 11(Suppl
1):P248 (10 November 2008)

Effects of different meal compositions and fasted state
on the oral bioavailability of etravirine.

Burton C, Eccles-James I, Nelson M, Bower M, Gotch F &
Imani N

Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS,
Imami N.

HIV Medicine 2008, 9 (Suppl 1): 41

Pharmacotherapy. 2008 Oct;28(10):1215-22.

Effects of recombinant human growth hormone on HIV1-specific T-cell responses, thymic output and proviral
DNA in patients on HAART: 48-week follow-up
J Immune Based Ther Vaccines. 2008; 6:7

Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE,
Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A,
Brett-Smith H.

Efficacy and safety of entecavir for chronic HBV in HIV/
HBV coinfected patients receiving lamivudine as part of
antiretroviral therapy.
AIDS. 2008 Sep 12;22(14):1779-87.

Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D,
Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V

Functional and phenotypic profiling of suppressive
regulatory T cells in a cohort of HIV-1 Infected

Macdonald DC, Nelson M, Bower M, Powles T.

Hepatocellular carcinoma, human immunodeficiency
virus and viral hepatitis in the HAART era.
World J Gastroenterol. 2008 Mar 21;14(11):1657-1663
Moyle G, Randell P

HIV and Cardiovascular risk

Clinical Medicine 2008;8:315-8.
Harania RS, Karuru J, Nelson M, Stebbing J.

HIV, hepatitis B and hepatitis C coinfection in Kenya
AIDS. 2008 Jun 19;22(10):1221-2.

Efficacy and tolerability of long-term efavirenz plus
nucleoside reverse transcriptase inhibitors for HIV-1

Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M,
Dezube BJ

Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ.

Barber TJ, Menon-Johanson A, Barton S

PLoS Med. 2008 Mar 18;5(3):e50.

Br J Gen Pract. 2008 May: 58 (550): 365

AIDS. 2008 Jan 11;22(2):275-9

Episodic sexual transmission of HIV revealed by
molecular phylodynamics.


HIV-associated multicentric Castleman’s disease
Am J Hematol. 2008; 83(6):498-503

How can we remove barriers to HIV testing outside of
GUM setting?



Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Stebbing
J, Powles T, Pantanowitz L

Naresh KN, Rice AJ, Bower M.

Clin Genitourin Cancer. 2008, 6(2):86-90

Am J Surg Pathol. 2008 Jul;32(7):1006-12

Human immunodeficiency virus-associated renal cell
carcinoma: a transatlantic case series.

Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes
P, Ozzard A, Nelson M, Gazzard B, Powles T
Immunological recovery in survivors following
chemotherapy for AIDS related non Hodgkin’s
Blood. 2008 Jan 2;

Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P,
Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I,
Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study
Impact of reverse transcriptase resistance on the
efficacy of TMC125 (etravirine) with two nucleoside
reverse transcriptase inhibitors in protease inhibitornaïve, nonnucleoside reverse transcriptase inhibitorexperienced patients: study TMC125-C227.
HIV Med. 2008 Nov;9(10):883-96

Strategies for Management of Antiretroviral Therapy
(SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W,
Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN

Inferior clinical outcome of the CD4+ cell count-guided
antiretroviral treatment interruption strategy in the
SMART study: role of CD4+ Cell counts and HIV RNA
levels during follow-up.
J Infect Dis. 2008 Apr 15;197(8):1145-55
Scott C, Grover D, Nelson M.

Is there a role for etravirine in patients with
Nonnucleoside reverse transcriptase inhibitor
AIDS. 2008 May 11;22(8):989-90.

Asghar A, Bower M, Gazzard B, Holmes P, Isenman H &
Nelson M.
Lipid lowering effect of ezetimibe in patients with
HAART-associated dyslipidaemias
HIV Medicine 2008 9 (Suppl 1): 33.

Goodier M, Gregson J, Constantinou D, Steel A, Bower M,
Gazzard B & Gotch F

Lipopolysaccharide-induced activation of natural killer
cells from HIV-1 infected individuals
HIV Medicine 2008, 9 (Suppl 1): 41

Lymph nodes involved by multicentric Castleman
disease among HIV-positive individuals are often
involved by Kaposi sarcoma

Strategies for Management of Antiretroviral Therapy
(SMART) Study Group, Emery S, Neuhaus JA, Phillips AN,
Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M,
Losso MH, Palfreeman A, Wood R.
Major clinical outcomes in antiretroviral therapy (ART)naive participants and in those not receiving ART at
baseline in the SMART study
J Infect Dis. 2008 Apr 15;197(8):1133-44
Pozniak A.

Management of HIV: still a long way to go
Br J Hosp Med (Lond). 2008 Mar;69(3):126

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus
E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M,
Montana JB, McHale M, Sullivan J, Ridgway C, Felstead
S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study

Maraviroc for previously treated patients with R5 HIV-1
N Engl J Med. 2008 Oct 2;359(14):1429-41

FM Burns, A Johnson, J Nazroo, K Fenton; on behalf
of the SONHIA collaboration group (J. Ainsworth, J.
Anderson, R. Arthur M. Chikohora, A. Fakoya, I.Fakoya,
A. Hughes, E. Jungmann, S. Manney, L. Muromba, N.
Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K.
Missed opportunities for earlier HIV diagnosis within
primary and secondary health care settings in the UK. 
AIDS 2008; 22:115-22.

Molina J-M, Andrade-Villanueva J, Echevarria J,
Chetchotisakd P, Corral J, David N, Moyle G, Mancini M,
Percival L, Yang R, Thiry A, McGrath D, for the CASTLE Study
Once-daily atazanavir/ritonavir versus twice-daily
lopinavir/ritonavir, each in combination with tenofovir
and emtricitabine, for management of antiretroviralnaive HIV-1-infected patients: 48 week efficacy and
safety results of the CASTLE study
The Lancet 2008: 372:646-55

Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J,
Schechter M.
Overcoming resistance to existing therapies in HIVinfected patients: the role of new antiretroviral
J Med Virol. 2008;80:565-76.




2008 continued
Coyne, KM, Cohen CE, Smith NA, Barton SE.
Patient-delivery partner medication
Int. J. STD & AIDS 2008;19:646

Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M,
Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin
C, Anderson J, Schwenk A, Leen C, Sabin CA; on behalf
of the UK Collaborative HIV Cohort (CHIC) Study Steering
Patterns and predictors of the use of different
antiretroviral drug regimens at treatment initiation in
the UK.
HIV Med. 2008 Jan;9(1):47-56.

Dickinson L, Boffito M, Khoo SH, Schutz M, Aarons LJ,
Pozniak AL, Back DJ
Pharmacokinetic analysis to assess forgiveness of
boosted saquinavir regimens for missed or late
J Antimicrob Chemother. 2008 Jul;62(1):161-7
Sousa M, Pozniak A, Boffito M.

Pharmacokinetics and pharmacodynamics of drug
interactions involving rifampicin, rifabutin and
antimalarial drugs.

J Antimicrob Chemother. 2008 Nov;62(5):872-8. Epub 2008
Aug 18
Singh K, Dickinson L, Chaikan A, Back D, Fletcher C, Pozniak
A, Moyle G, Nelson M, Gazzard B, Herath D, Boffito M.

Pharmacokinetics and safety of saquinavir/ritonavir and
omeprazole in HIV-infected subjects
Clin Pharmacol Ther. 2008 Jun;83(6):867-72.

Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak
A, Gazzard B, Moyle G
Pharmacokinetics of atazanavir/ritonavir once daily
and lopinavir/ritonavir twice and once daily over 72 h
following drug cessation.
Antivir Ther. 2008;13(7):901-7
Boffito M, Miralles D, Hill A.

Pharmacokinetics, efficacy, and safety of darunavir/
ritonavir 800/100 mg once-daily in treatment-naive and
experienced patients.
HIV Clin Trials. 2008 Nov-Dec;9(6):418-27.

V. Campbell, J. Krell, M. Stancliffe, M. Atkins, M. Habibi, M.
Nelson, B. Gazzard, M.Bower
Plasma HHV8 DNA viral load as a tumour marker for
multicentric Castleman’s disease MCD
HIV Medicine 2008, 9 (Suppl 1): 7.

Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M,
Tsoukas C.

Potential for new antiretrovirals to address unmet needs
in the management of HIV-1 infection.
AIDS Patient Care STDS 2008;22:459-71

El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ,
Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD

Risk for opportunistic disease and death after
reinitiating continuous antiretroviral therapy in patients
with HIV previously receiving episodic therapy: a
randomized trial.
Ann Intern Med. 2008 Sep 2;149(5):289-99

Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG,
Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ,
Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE,
Choudhri S.

Safety, tolerability, pharmacokinetics, and efficacy of
an interleukin-2 agonist among HIV-infected patients
receiving highly active antiretroviral therapy.
J Interferon Cytokine Res. 2008 Feb;28(2):89-100

Underwood J, Scourfield A, Bell C, Harding V, Bower M &
Nelson M
Severe hepatotoxicity associated with darunavir
HIV Medicine 2008, 9 (Suppl 1): 18

Byakika-Kibwika P, Lamorde M, Kalemeera F, D‘Avolio A,
Mauro S, Di Perri G, Ryan M, Mayanja-Kizza H, Khoo S, Back
D, Boffito M, Merry C.

Steady-state pharmacokinetic comparison of generic
and branded formulations of stavudine, lamivudine and
nevirapine in HIV-infected Ugandan adults.
J Antimicrob Chemother. 2008 Nov;62(5):1113-7.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I,
Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F,
Trottier B, Bellos N, Saag M, Cooper DA, Westby M,
Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead
S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2
Study Teams.
Subgroup analyses of maraviroc in previously treated
R5 HIV-1 infection.
N Engl J Med. 2008 Oct 2;359(14):1442-55




Ewings FM, Bhaskaran K, Nock, Porter K, D, McLean K,
Hawkins D, Fisher M, Fidler S, Gilson R, Brettle R, Johnson
M, Phillips A

Stebbing J, Ngan S, Ibrahim H, Charles P, Nelson M,
Kelleher P, Naresh KN, Bower M.

AIDS. 2008 Jan 2;22(1):89-95

Clin Exp Immunol. 2008, 154(3):399-405.

Survival following HIV infection of a cohort followed up
from seroconversion in the UK

The successful treatment of haemophagocytic syndrome
in patients with human immunodeficiency virusassociated multi-centric Castleman‘s disease

Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG,
Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.

V. Campbell, J. Krell, A. Scourfield, S. Mandalia, M. Nelson, T.
Powles, J.Stebbing, M. Bower

Switching from twice-daily abacavir and lamivudine
to the once-daily fixed-dose combination tablet of
abacavir and lamivudine improves patient adherence
and satisfaction with therapy.
HIV Med. 2008 Oct;9(8):667-72.

Kavouni A, Catalan J, Brown S, Mandalia S, Barton SE

The use of antidepressants and risk of cancer in
individuals infected with the human immunodeficiency
HIV Medicine 2008, 9 (Suppl 1): 25 2008

Cohen CE, Coyne KM, Mandalia S, Waters AM, Sullivan AK

The face of HIV and AIDS: can we erase the stigma?

Time to use text reminders in genitourinary medicine

Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B,
Moyle G.

Lagos D, Vart RJ, Gratrix F, Westrop SJ, Emuss V, Wong PP,
Robey R, Imami N, Bower M, Gotch F, Boshoff C

AIDS Care. 2008 Apr; 20 (4) 485-7

The impact of HIV tropism on decreases in CD4 cell
count, clinical progression, and subsequent response to
a first antiretroviral therapy regimen.
Clin Infect Dis. 2008;46:1617-23

J.Krell, A. Bazeos, V. Campbell, V. Harding, T. Powles, J.
Stebbing, S. Mandalia, M. Bower.

The incidence of HIV-associated multicentric Castlemans
HIV Medicine 2008, 9 (Suppl 1): 7 2008

Waters L, Nelson M, Mandalia S, Bower M, Powles T,
Gazzard B, Stebbing J.

The risks and incidence of K65R and L74V mutations
and subsequent virologic responses
Clin Infect Dis. 2008 Jan 1;46(1):96-100

Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG.
The role of transbronchial fine needle aspiration in an
integrated care pathway for the assessment of patients
with suspected lung cancer
J Thorac Oncol. 2006; 1(4):324-7.

Turner C, Cohen CE, Sabin C, Tosswill J, Best J, Taylor G, de
Ruiter A, Barlow D, Smith NA. 
The Seroepidemiology of HTLV-1 amongst
genitourinary attendees in South East London.

Journal of Clinical Virology. 2008 Oct;43(2):253-4. Epub
2008 Aug 8

Int J STD AIDS 2008 Jan; 19 (1): 12-3.

Toll-like receptor 4 mediates innate immunity to Kaposi
sarcoma herpesvirus
Cell Host Microbe. 2008 Nov 13;4(5):470-83

Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V,
Higgins N, Grundy A, Moyle GJ

Treatment of Altered Body Composition in HIVAssociated Lipodystrophy: Comparison of
Rosiglitazone, Pravastatin, and Recombinant Human
Growth Hormone
HIV Clin Trials 2008;9(4):253–267

Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels
M, Kinghorn G, McCarron B, Pozniak A, Tang A, Walsh J,
Williams I, Gazzard B.
Treatment outcome and cost-effectiveness of different
highly active antiretroviral therapy regimens in the UK
Int J STD AIDS. 2008 May;19(5):297-304.

United Kingdom Collaborative HIV Cohort Study, Lee KJ,
Dunn D, Porter K, Bansi RG, Hill T, Phillips AN, Sabin CA,
Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B,
Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C.

Treatment switches after viral rebound in HIV-infected
adults starting antiretroviral therapy: multicentre cohort
AIDS. 2008 Oct 1;22(15):1943-50.

Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard
B, Stebbing J
Triple-class antiretroviral agent resistance in a large
cohort: prevalence and clinical outcomes.
Arch Intern Med. 2008, ;168(17):1926-7.




2008 continued
Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B,
Bower M

Use of antidepressants and risk of cancer in individuals
infected with HIV
J Clin Oncol. 2008 May 10;26(14):2305-10

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S,
Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART
Study Group.

Viral resuppression and detection of drug resistance
following interruption of a suppressive non-nucleoside
reverse transcriptase inhibitor-based regimen
AIDS. 2008 Nov 12;22(17):2279-89.

Ancock B, Bower M, Gazzard BG, Nelson M

Vitamin D deficiency in the in-patients HIV population:
cause or effect?
Journal of the International AIDS Society 2008, 11(Suppl
1):P116 (10 November 2008)
Bhattacharya R, Barton SE, Catalan J

When good news is bad news: psychological impact of
false positive diagnosis of HIV
AIDS Care. 2008 May; 20(5): 560-4